Laboratory of Respiratory Cell Biology, Cardiac, Thoracic and Vascular Department, University of Pisa, Via Paradisa, 2, 56124 Pisa, Italy.
Cardiovasc Res. 2012 Jun 1;94(3):537-44. doi: 10.1093/cvr/cvs125. Epub 2012 Mar 16.
Microparticles are membrane vesicles shed by cells upon activation and/or apoptosis. Microparticles are involved in several processes, including blood coagulation and thrombosis. In addition to their role in the regulation of lipid metabolism, peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists exert other effects, both dependent on and independent of PPAR-γ activation. Some PPAR-γ agonists have been linked to an increased risk of thrombotic diseases. We aimed to investigate the potential role of PPAR-γ agonists on the generation of procoagulant microparticles by human monocytes/macrophages.
Monocytes/macrophages were isolated from the buffy coats of normal donors. Cells were incubated with three structurally unrelated PPAR-γ agonists, namely, rosiglitazone, pioglitazone, and 15-deoxy-Δ(12,14)-prostaglandin J(2). Microparticle generation was assessed as phosphatidylserine concentration by a prothrombinase assay, after capturing the microparticles onto annexin V-coated wells. Intracellular calcium concentration was assessed by a fluorescent probe. Extracellular signal-regulated kinase (ERK) phosphorylation was assessed by western blot. Tissue factor expression on microparticles was measured with a one-stage clotting assay. Rosiglitazone and 15-deoxy-Δ(12,14)-prostaglandin J(2), but not pioglitazone, caused a dose-dependent, significant increase in intracellular calcium mobilization and tissue factor-bearing microparticle generation. EGTA inhibited microparticle generation. The specific PPAR-γ inhibitor, GW9662, also inhibited microparticle generation. Finally, rosiglitazone and 15-deoxy-Δ(12,14)-prostaglandin J(2) caused phosphorylation of ERK; inhibition of ERK by PD98059 inhibited microparticle generation.
The PPAR-γ agonists rosiglitazone and 15-deoxy-Δ(12,14)-prostaglandin J(2), but not pioglitazone, caused an increase in procoagulant, tissue factor-bearing microparticle generation by human monocytes/macrophages. The effect was dependent on ERK phosphorylation and partly mediated through intracellular calcium mobilization; however, direct activation of the PPAR-γ ligand was also involved.
微粒体是细胞在激活和/或凋亡时释放的膜囊泡。微粒体参与多种过程,包括血液凝固和血栓形成。除了在脂质代谢调节中的作用外,过氧化物酶体增殖物激活受体-γ(PPAR-γ)激动剂还具有其他作用,这些作用既依赖于也不依赖于 PPAR-γ 的激活。一些 PPAR-γ 激动剂与血栓性疾病风险增加有关。我们旨在研究 PPAR-γ 激动剂对人单核细胞/巨噬细胞产生促凝微粒体的潜在作用。
从正常供体的白细胞层中分离单核细胞/巨噬细胞。用三种结构上不相关的 PPAR-γ 激动剂,即罗格列酮、吡格列酮和 15-脱氧-Δ(12,14)-前列腺素 J(2)孵育细胞。通过捕获微粒体到 annexin V 包被的孔上来评估微粒体生成作为磷脂酰丝氨酸浓度,通过凝血酶原酶测定法进行评估。通过荧光探针评估细胞内钙离子浓度。通过 Western blot 评估细胞外信号调节激酶(ERK)磷酸化。用一步凝血测定法测量微粒体上的组织因子表达。罗格列酮和 15-脱氧-Δ(12,14)-前列腺素 J(2),但不是吡格列酮,导致细胞内钙离子动员和组织因子携带的微粒体生成呈剂量依赖性显著增加。EGTA 抑制微粒体生成。特异性 PPAR-γ 抑制剂 GW9662 也抑制微粒体生成。最后,罗格列酮和 15-脱氧-Δ(12,14)-前列腺素 J(2)引起 ERK 磷酸化;PD98059 抑制 ERK 抑制微粒体生成。
PPAR-γ 激动剂罗格列酮和 15-脱氧-Δ(12,14)-前列腺素 J(2),但不是吡格列酮,导致人单核细胞/巨噬细胞产生促凝、组织因子携带的微粒体增加。该作用依赖于 ERK 磷酸化,部分通过细胞内钙离子动员介导;然而,也涉及 PPAR-γ 配体的直接激活。